Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Filings indexed 1,091 across all filing types
Latest filing 2025-01-17 Director's Dealing
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-01-17 English
Director's Dealing 2025
Director's Dealing
2025-01-03 English
Director's Dealing 2025
Director's Dealing
2025-01-03 English
Director's Dealing 2025
Director's Dealing
2025-01-03 English
Board/Management Information 2024
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content specifically discusses the voluntary forfeiture of cash bonuses by two officers and the related decision by the Compensation Committee. This relates to changes in compensatory arrangements of certain officers, which falls under management or board-related announcements. The document does not contain financial statements or detailed financial data, nor is it an earnings release or annual report. It is not a proxy statement or remuneration report but rather an announcement of management decisions. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length is under 5,000 characters and contains substantive information about management decisions, not just a report publication announcement or regulatory filing. Confidence is high due to clear identification of the filing type and content focus.
2024-12-23 English
3
Director's Dealing
2024-12-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.